Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;19(3):471-478.
doi: 10.1016/j.jsxm.2022.01.003. Epub 2022 Feb 5.

The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer

Jose M Flores  1 , Helen L Bernie  1 , Eduardo Miranda  1 , Bruno Nascimento  1 , Elizabeth Schofield  2 , Nicole Benfante  1 , Sigrid Carlsson  3 , John P Mulhall  4
Affiliations

The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer

Jose M Flores et al. J Sex Med. 2022 Mar.

Abstract

Background: Prostate-specific antigen (PSA) secretion is a testosterone (T) dependent process. Published data suggest that a low T level is an independent predictor of higher-grade prostate cancer (PC).

Aim: To evaluate the relationship between T and PSA in patients with PC.

Methods: All men diagnosed with PC with a recorded pre-treatment total T level measurement were included in this analysis. We analyzed demographic, clinical, and pathological data. Patients were stratified according to pretreatment PSA levels: <2 ng/mL, 2-4 ng/mL, >4 ng/mL. Low T was defined as total T < 10.4 nmol/L (300 ng/dL), very low T < 6.9 nmol/L (200 ng/dL).

Outcomes: T levels by PSA groups according to the PC pathology.

Results: In this retrospective study, mean patient age was 61 years among 646 men. The distribution by PSA group was: 8% (<2), 17% (2-4), and 76% (>4). The mean T level across the entire cohort was 13 nmol/L (374 ng/dL). Overall, 30% had a T level < 10.4 nmol/L (300 ng/dL). The mean total T level by PSA group was: <2 ng/mL, 7 nmol/L (206 ng/dL); 2-4 ng/mL, 13 nmol/L (362 ng/dL); >4 ng/mL, 14 nmol/L (393 ng/dL), P < .001. PSA <4 ng/mL was a significant predictor of low T in men with PC GS ≥8. PSA <2 ng/mL was a significant predictor of very low T independent of the PC pathology.

Clinical implications: These findings suggest that clinicians should consider measuring T levels when a patient diagnosed with PC GS ≥8 and PSA level <4 ng/mL, and for each patient with PSA level <2 ng/mL independent of the PC pathology.

Strengths & limitations: Our study has several strengths including (i) inclusion of a large population of men, (ii) use of a database which is audited and reviewed for accuracy annually, and (iii) use of an accurate T assay (LCMS). Nonetheless, there are limitations: (i) the subjects of the study are from a single institution, and (ii) we did not measure free T levels.

Conclusion: In men with PC with GS ≥8, PSA level <4 ng/mL predicts low T. PSA <2 ng/mL predicts very low T independent of the PC pathology. Flores JM, Bernie HL, Miranda E, et al. The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer. J Sex Med 2022;19:471-478.

Keywords: Hypogonadism; PSA; Prostate Cancer; Testosterone; Testosterone Deficiency.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None of the authors declare to have a conflict of interest. No disclosures.

Figures

Figure 1.
Figure 1.
Prevalence of low Testosterone among PSA Groups and According to Gleason Sum Pathology
Figure 2:
Figure 2:
Relationship between Testosterone levels, and PSA Stratified by Prostate Cancer Pathology
See this image and copyright information in PMC

Comment in

References

    1. Kaplan AL, Hu JC, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F. Testosterone Therapy in Men With Prostate Cancer. Eur Urol. 2016;69: 894–903. - PMC - PubMed
    1. Konety BR, Bird VY, Deorah S, Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol. 2005;174: 1785–8; discussion 88. - PubMed
    1. Gatling RR. Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology. South Med J. 1990;83: 782–4. - PubMed
    1. Rebbeck TR, Haas GP. Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol. 2014;21: 7496–506. - PMC - PubMed
    1. Kwong JCC, Krakowsky Y, Grober E. Testosterone Deficiency: A Review and Comparison of Current Guidelines. J Sex Med. 2019;16: 812–20. - PubMed

Publication types